Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder
with no current cure. One of the important therapeutic approaches of AD is the inhibition of β …

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Sulfoximines have been largely disregarded in medicinal chemistry for a long time.
However, recently, they have risen to the apparent level of stardom on the drug discovery …

The carbamate group is a key structural motif in many approved drugs and prodrugs. There
is an increasing use of carbamates in medicinal chemistry and many derivatives are …

Intracellular accumulation of tau is a hallmark pathology in Alzheimer disease (AD) and the
related tauopathies, thus targeting tau could be promising for drug development. Proteolysis …

Alzheimer's disease, a major and increasing global health challenge, is an irreversible,
progressive form of dementia, associated with an ongoing decline of brain functioning. The …

The aggregation of specific proteins is hypothesized to underlie several degenerative
diseases, which are collectively known as amyloid disorders. However, the mechanistic …

An increase in dementia numbers and global trends in population aging across the world
prompts the need for new medications to treat the complex biological dysfunctions, such as …

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by
neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were …

Alzheimer's disease (AD) is the most common cause of dementia and cognitive impairment;
yet, there is currently no treatment. A buildup of Aβ, tau protein phosphorylation, oxidative …